The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al

Ann Rheum Dis. 2021 Jan;80(1):e3. doi: 10.1136/annrheumdis-2020-217545. Epub 2020 Apr 27.
No abstract available

Keywords: arthritis, rheumatoid; immune system diseases; inflammation.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • COVID-19 Drug Treatment*
  • Humans
  • India / epidemiology
  • Interleukin-6
  • Pandemics
  • Rheumatic Diseases* / drug therapy
  • Rheumatic Diseases* / epidemiology
  • Rheumatology*
  • SARS-CoV-2

Substances

  • Antirheumatic Agents
  • Interleukin-6